Evotec and CHDI Foundation Extend Collaboration on Huntington’s Disease Research

Evotec SE and CHDI Foundation have announced an extension of their 20-year collaboration aimed at developing therapies for Huntington’s disease. CHDI Foundation is a nonprofit dedicated to Huntington’s disease research. This extended collaboration intends to deepen scientific understanding and aid in the development of new treatments.

Evotec’s neuroscience platform will be leveraged alongside various services, including target validation, stem-cell research, and biomarker discovery. The partnership stands as one of Evotec's largest alliances in drug discovery. Originally initiated in 2006, it incorporates multiple facets of biology and chemistry research.

Dr. Craig Johnstone, COO of Evotec, acknowledged the importance of the collaboration, emphasizing their joint commitment to innovative therapies. Dr. Robert Pacifici, CSO at CHDI, highlighted Evotec's crucial role in CHDI’s preclinical research over the past two decades and expressed optimism for future advancements.